Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?
Sabah AlaklabiArya Mariam RoyLubna Naaz ChaudharyShipra GandhiPublished in: Exploration of targeted anti-tumor therapy (2023)
Pembrolizumab combined with chemotherapy has been established as the preferred first-line therapy for treating metastatic triple-negative breast cancer (mTNBC) with programmed cell death ligand-1 (PD-L1)-positive disease since its approval for that indication. However, the optimal sequencing of therapy remains an unanswered question for a subset of mTNBC patients who harbor germline breast cancer gene 1/2 ( BRCA1/2 ; gBRCA1/2 ) mutation. This article aims to offer insights into the optimal therapy sequencing for mTNBC patients with gBRCA1/2 mutations and its impact on clinical decision-making. The perspective offered is based on the best currently available data and propose a practical algorithm to guide the management of this subgroup in the frontline setting.
Keyphrases
- decision making
- small cell lung cancer
- squamous cell carcinoma
- machine learning
- randomized controlled trial
- clinical trial
- copy number
- gene expression
- electronic health record
- transcription factor
- dna damage
- breast cancer risk
- smoking cessation
- young adults
- tyrosine kinase
- study protocol
- rectal cancer
- replacement therapy
- neural network
- phase iii